Instruction for use: Setegis

Trade name of the drug – Setegis

Active substance: Terazosinum

Dosage Form: tablets

Composition (per tablet): active substance: terazosin hydrochloride dihydrate - 2.374 mg; 5,935 mg

(Equivalent to 2 mg or 5 mg terazosin, respectively)

Excipients: lactose monohydrate - 110/110 mg; starch, pre-gelatinized maize - 40/40 mg; povidone K30 - 5.5 mg; Magnesium stearate - 2.2 mg; talc - 2/2 mg

Table. 2 mg also contain: quinoline yellow dye - 0.05 mg

Table. 5 mg also contain: dye "sunset" yellow - 0.01 mg

Pharmacotherapeutic group:

Alpha1-blocker [alpha-blockers]

Alpha1-blocker [Drugs affecting the metabolism of the prostate gland and correctors urodynamics]

ATX G04CA03 Terazosin

The nosological classification (ICD-10)

I10 Essential (primary) hypertension: hypertension; Arterial hypertension; Arterial hypertension crisis course; Essential Hypertension; Essential hypertension; Essential hypertension; Essential hypertension; Essential hypertension; Primary hypertension; Arterial hypertension, complications of diabetes; The sudden increase in blood pressure; Hypertensive disorders of blood circulation; hypertensive condition; hypertensive crises; arterial Hypertension; malignant Hypertension; Hypertonic disease; hypertensive crises; accelerated hypertension; malignant hypertension; The aggravation of hypertensive disease; Transient hypertension; Isolated systolic hypertension

I15 Secondary hypertension: Arterial hypertension, complications of diabetes; hypertension; The sudden increase in blood pressure; Hypertensive disorders of blood circulation; hypertensive condition; hypertensive crises; hypertension; arterial Hypertension; malignant Hypertension; hypertensive crises; accelerated hypertension; malignant hypertension; The aggravation of hypertensive disease; Transient hypertension; hypertension; Arterial hypertension; Arterial hypertension crisis course; renovascular hypertension; Hypertension symptomatic; Renal hypertension; Renovascular hypertension; renovascular hypertension; Symptomatic hypertension

N40 Hyperplasia of prostate gland: Prostate adenoma; BPH; Prostatauxe; prostate Hypertrophy; Dysuric disorders caused by benign prostatic hyperplasia; Dizuricheskie disorder with benign prostatic hyperplasia; Dysuria with prostate cancer; Benign prostatic giperpalaziya; Benign prostatic hyperplasia; Benign prostatic hyperplasia stages 1 and 2; Benign prostatic hyperplasia I degree; Benign prostatic hyperplasia II degree; Benign prostatic hypertrophy; The disease of the prostate gland; Acute urinary retention related to benign prostatic hyperplasia; Benign prostatic hyperplasia stages 1 and 2 in combination with prostatitis; paradoxical ischuria

Pharmacological Properties of Setegis

Pharmachologic effect - Mode of action - alpha adrenoliticheskoe.

Setegis Dosage and Administration

Inside. The tablet should be swallowed entirely, not chewing.

The daily dose should be selected individually, depending on the blood pressure of the patient.

The initial dose for adults

If both readings of 1 mg taken at bedtime. The initial dose should not exceed 1 mg in an increased risk of hypotensive episodes after the first dose. The daily dose can be gradually increased, approximately doubling the dose at weekly intervals until the target blood pressure.

The maintenance dose for adults

Hypertension: usually from 2 to 10 mg 1 time per day. Doses of 20 mg rarely improve the efficiency of the drug, doses over 40 mg have not been studied.

BPH: maintenance dose is usually 5-10 mg 1 time per day. The present data showing the effect of additional symptomatic drug at a dose greater than 10 mg / day, no. In the elderly and patients with renal failure dose adjustment is required.

Release Form

Tablets, 2 mg and 5 mg. According to Table 10. in a blister made of PVC / PVDC / Aluminium foil. 3 blisters in a carton box.

Manufacturer

CJSC "Pharmaceutical plant EGIS." 1106 Budapest, ul. Keresturi, 30-38, Hungary.

Representative office of JSC "Pharmaceutical plant EGIS" (Hungary) in Moscow. 121108, Moscow, ul. Ivan Franko, 8.

Storage conditions of Setegis

At a temperature of 15-30 ° C.

Keep out of the reach of children.

Shelf life

3 years.

Do not use beyond the expiration date printed on the package.

Conditions of supply of pharmacies

On prescription.